61 related articles for article (PubMed ID: 420951)
1. Pharmacokinetic parameters: potential for and problems with their use as predictors of response to cancer chemotherapeutic agents.
Creaven PJ
Bull Cancer; 1979; 66(1):85-8. PubMed ID: 420951
[TBL] [Abstract][Full Text] [Related]
2. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
Gardner SN
Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetic aspects of tumor tissue impairment by cancerostatics. Ways for the intensification of the induced attack in the multiple step cancer therapy. CMT-Selectine].
von Ardenne M; von Ardenne A
Arzneimittelforschung; 1975 Jun; 25(6):863-70. PubMed ID: 240367
[TBL] [Abstract][Full Text] [Related]
6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
7. Optimal prescription method for cancer chemotherapy.
Vriesendorp HM
Exp Hematol; 1985; 13 Suppl 16():57-63. PubMed ID: 3857184
[TBL] [Abstract][Full Text] [Related]
8. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator.
Adams DJ
Cancer Res; 1989 Dec; 49(23):6615-20. PubMed ID: 2819712
[TBL] [Abstract][Full Text] [Related]
9. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
Cagnoni PJ; Matthes S; Day TC; Bearman SI; Shpall EJ; Jones RB
Bone Marrow Transplant; 1999 Jul; 24(1):1-4. PubMed ID: 10435726
[TBL] [Abstract][Full Text] [Related]
10. [Significance of formation of micronuclei in SCC VII murine cells treated with various chemotherapeutic agents].
Jeremić B; Sibamoto J; Abe M
Srp Arh Celok Lek; 1996; 124(7-8):169-74. PubMed ID: 9102841
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
Norton L
Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
[TBL] [Abstract][Full Text] [Related]
12. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
14. Optimizing high-dose therapy using pharmacokinetic principles.
Zorsky PE; Perkins JB
Semin Oncol; 1993 Oct; 20(5 Suppl 6):2-18. PubMed ID: 8211213
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of cancer chemotherapy.
Alnaim L
J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
[TBL] [Abstract][Full Text] [Related]
16. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
Nagasaki K; Miki Y
Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
[TBL] [Abstract][Full Text] [Related]
17. Modelling and simulation of chemotherapy of haematological and gynaecological cancers.
Nani FK; Oğuztöreli MN
IMA J Math Appl Med Biol; 1999 Mar; 16(1):39-91. PubMed ID: 10335600
[TBL] [Abstract][Full Text] [Related]
18. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
19. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
20. Drug stability and compatibility in oncology care.
Williams DA
J Infus Chemother; 1996; 6(4):195-202. PubMed ID: 9229315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
